Navigation Links
Market for Cellular Therapies Will Grow at a Robust Annual Rate of More Than 30 Percent in the United States Through 2017
Date:12/2/2008

At Least 10 New Cellular Therapies Will Launch Over Next Decade, According to a New Report from Decision Resources

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cellular therapies drug market will experience robust growth in the United States over the next decade, reaching $1.5 billion in 2017. According to the new special report entitled Cellular Therapies, the launch of second-generation cellular therapies, the approval of novel stem-cell-based therapies and dendritic cell vaccines, and the continuous adoption of existing cellular products will drive this market to grow at an annual rate of least 31 percent in the United States from 2007 to 2017.

While market growth will be strong in the United States, new centralized regulations in Europe that take effect at the end of 2008 will introduce uncertainties for cellular therapies marketed in Europe, according to the report. Among emerging therapies, TiGenix's ChondroCelect will be the first therapy to be reviewed under the new centralized European Medicines Agency guidelines.

The report forecasts that, of the 10 or more cellular therapies that will launch over the next decade in the United States and/or Europe, Dendreon's Provenge will be the first market entrant following its approval for prostate cancer in 2009 in the United States. Another cellular therapy that will launch in the near-term, Osiris/Genzyme's Prochymal, will garner sales of $235 million in 2017 for the treatment of Crohn's disease, although its initial regulatory approval will be for graft-versus-host disease in 2010 in the United States and in 2011 in Europe.

"First-to-market cellular therapies have had disappointing sales performances to date," said Irene Koulinska, M.D., analyst at Decision Resources. "However, researchers have made significant progress in the development of cellular therapies in recent years, despite facing considerable financial and ethical challenges. Additionally, the availability of noncontroversial cell sources and the establishment of a regulatory framework in the United States and Europe have prompted increased interest among large biomedical companies in the development and commercialization of cellular therapies."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Decision Resources
    Christopher Comfort
    781-296-2597
    ccomfort@dresources.com

    Decision Resources, Inc.
    Elizabeth Marshall
    781-296-2563
    emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
2. Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference
3. LCA-Vision to Present at RBC Capital Markets 2008 Healthcare Conference
4. New Marketing Coaching and Consulting Firm for Physicians Practicing Concierge Medicine Launched Today
5. TEAC Forms Strategic Alliance With SST Group, Inc. to Distribute Its Next Generation Medical Disc Publishing Systems Into Medical Market
6. CCID Consulting Discusses Chinas Medical Equipment Market
7. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
8. STAR Marketing Announces New Breed of Healthcare Relationship Marketing Service
9. MINRAD International, Inc. Announces Termination of RxElite Holdings Inc. as Anesthetics Distributor for the Human Market in United States
10. Medicsight Announces New Global Marketing Partnership with Ziosoft Unveiled at RSNA 2008
11. Visage Imaging and Viatronix Sign Comprehensive Marketing Agreement for Virtual Colonoscopy Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: